Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and ...

Alignment on a national action plan would enable every sector—academia, industry, sites and care delivery, patient and other nonprofit organizations, government, communities, and the public—to ...

The American Medical Association (AMA) has welcomed the Trump administration’s AI Action Plan and believes that physicians ...

However, the requirements for Diversity Action Plans only apply to clinical studies for which enrollment commences after 180 days from the publication of the final guidance.

The U.S. Food and Drug Administration on Wednesday recommended steps for drugmakers and medical device makers to improve racial, ethnic and other diversity in their clinical trials.